Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues
Open Access
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 5 (1) , 8
- https://doi.org/10.1186/1476-0711-5-8
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationJournal of Hepatology, 2005
- Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation1Transplantation, 2004
- Adefovir Dipivoxil Therapy for Lamivudine–Resistant Hepatitis B in Pre- and Post-Liver Transplantation PatientsHepatology, 2003
- Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV)Journal of Hepatology, 2003
- Viral dynamics during and after entecavir therapy in patients with chronic hepatitis BJournal of Hepatology, 2002
- Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation – possible role of mutations in the YMDD motif prior totransplantation as a risk factor for reinfectionJournal of Hepatology, 2001
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- LONG-TERM FOLLOW-UP OF HEPATITIS B VIRUS-INFECTED RECIPIENTS AFTER ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 1994
- Hepatitis B virus reinfection after orthotopic liver transplantation: Serological and clinical implicationsJournal of Hepatology, 1992
- Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunizationJournal of Hepatology, 1991